Skip to main content

ADVERTISEMENT

Gina Tomaine

News
11/17/2022
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody...
11/17/2022
Oncology
09/28/2023
A regimen of natalizumab combined with corticosteroids was generally well-tolerated but did not improve outcomes for patients with newly diagnosed high-risk GI GVHD, according to a phase 2 study.
A regimen of natalizumab combined with corticosteroids was generally well-tolerated but did not improve outcomes for patients with newly diagnosed high-risk GI GVHD, according to a phase 2 study.
A regimen of natalizumab...
09/28/2023
Oncology
News
08/19/2022
Venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine demonstrated efficacy among older or unfit patients with newly diagnosed AML, according to results from a phase 2 trial.
Venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine demonstrated efficacy among older or unfit patients with newly diagnosed AML, according to results from a phase 2 trial.
Venetoclax added to cladribine...
08/19/2022
Oncology
News
10/27/2022
The FDA granted accelerated approval to teclistamab for the treatment of adult patients with relapsed or refractory MM who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
The FDA granted accelerated approval to teclistamab for the treatment of adult patients with relapsed or refractory MM who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...
The FDA granted accelerated...
10/27/2022
Oncology
News
09/30/2022
Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine regimen is not currently recommended for R/R CLL, according to a phase 2 study.
Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine regimen is not currently recommended for R/R CLL, according to a phase 2 study.
Triple therapy with...
09/30/2022
Oncology
News
09/14/2022
Ofatumumab plus bendamustine is an effective and well-tolerated combination therapy for the first-line treatment of older patients with mantle cell lymphoma, according to a phase 2 study.
Ofatumumab plus bendamustine is an effective and well-tolerated combination therapy for the first-line treatment of older patients with mantle cell lymphoma, according to a phase 2 study.
Ofatumumab plus bendamustine is...
09/14/2022
Oncology
News
07/13/2022
Findings from a phase 2 trial show zanubrutinib demonstrates deep and durable responses and a favorable safety profile in relapsed/refractory MCL at a median follow-up of 35.3 months.
Findings from a phase 2 trial show zanubrutinib demonstrates deep and durable responses and a favorable safety profile in relapsed/refractory MCL at a median follow-up of 35.3 months.
Findings from a phase 2 trial...
07/13/2022
Oncology
News
12/06/2022
The FDA granted approval to olutasidenib for adult patients with relapsed/refractory AML and a susceptible IDH1 mutation, as detected by an FDA-approved test.
The FDA granted approval to olutasidenib for adult patients with relapsed/refractory AML and a susceptible IDH1 mutation, as detected by an FDA-approved test.
The FDA granted approval to...
12/06/2022
Oncology
News
09/08/2023
Improved first-line clinical strategy for treating patients with lower-risk MDS would be beneficial, according to a global, retrospective study presented at the Society of Hematologic Oncology 2023 Annual Meeting.
Improved first-line clinical strategy for treating patients with lower-risk MDS would be beneficial, according to a global, retrospective study presented at the Society of Hematologic Oncology 2023 Annual Meeting.
Improved first-line clinical...
09/08/2023
Oncology
News
08/23/2022
Zanubrutinib significantly improved PFS vs bendamustine–rituximab, with an acceptable safety profile, as a frontline therapy for patients with CLL and SLL, according to results from the phase 3 SEQUOIA trial.
Zanubrutinib significantly improved PFS vs bendamustine–rituximab, with an acceptable safety profile, as a frontline therapy for patients with CLL and SLL, according to results from the phase 3 SEQUOIA trial.
Zanubrutinib significantly...
08/23/2022
Oncology